NCT07121569View on ClinicalTrials.gov

Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 6, 2024

Primary Completion Date

March 4, 2025

Study Completion Date

March 13, 2025

Conditions

Ischemic Stroke, Acute

Interventions

DRUG

Oral lumbrokinase DLBS1033

DLBS1033: 490 mg, DISOLF film-coated tablet, Dexa Medica, 2 tabs t.i.d

DRUG

Placebo

Placebo by Dexa Medica, 2 tabs t.i.d.

Trial Locations (1)

57126

Dr. Moewardi Regional General Hospital, Surakarta

All Listed Sponsors

lead

Universitas Sebelas Maret

OTHER

NCT07121569 - Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes | Biotech Hunter | Biotech Hunter